Purple Biotech LTD. PPBT
Purple Biotech LTD. (Nasdaq: PPBT) is an oncology drug developer. Its lead program, NT219, is in Phase 2 for Recurrent/metastatic squamous cell carcinoma of the head and neck.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NT219 (IRS1/2 and STAT3 inhibitor) | R/M SCCHN | small molecule | Phase 2 |
| CM24 (anti-CEACAM1 antibody) | Pancreatic ductal adenocarcinoma | antibody | Phase 2 |
| IM1240 (capped CD3x5T4xNKG2A tri-specific) | Solid tumors | antibody | Pre-clinical |
| IM1305 (capped CD3xTROP2xNKG2A tri-specific) | Solid tumors | antibody | Pre-clinical |
Recent results and decisions
- Nov 19, 2025mixed Re-presented randomized Phase 2 (n=31): ORR 25% vs 6.7%, DCR 62.5% vs 46.7%, OS HR 0.81 and PFS HR 0.75 in the full population (primary endpoint OS not statistically significant); post-hoc CEACAM1-enriched subgroup OS HR 0.22 (p=0.006).
Higher objective response rate ( ORR) (25% vs 6.7% )
Filing - Nov 19, 2025positive Re-presented Phase 1 dose-escalation data: no DLTs, 2 confirmed PRs among 8 patients at active doses (ORR 25%, DCR 62.5%); Phase 2 initiated June 2025.
ORR: 25 %, DCR: 62.5 %
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.